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Basal cell carcinoma (BCC) is the most common cancer among skin cancers. The 
incidence of cutaneous malignant melanoma (CMM) and non-melanoma skin cancer 
(NMSC) has increased more than 600% worldwide since the 1940s. Carcinogenesis is a 
multi-step process involving multiple genetic alterations. The connection between cell 
cycle proliferation and cancer resulting in deregulated cellular proliferation leads to 
cancer. Cancer has been associated with disturbances in cell cycle regulation. Recent 
studies have shown that p16, CDK6 and CCND1 mRNA genes and protein expression are 
involved in the tumorgenesis of skin cancer. These genes play a role in cell cycle 
proliferation. In this study, we assessed the expression of a cyclin, a cyclin dependent 
kinase, and a cyclin kinase inhibitor in skin BCC tissue. Reverse Transcription in situ 
polymerase chain reaction (RT in situ PCR) and immunohistochemistry (IHC) were used 
to detect the expression of p16, CDK6 and CCND1 mRNA genes through them of protein 
expression in human skin BCC tissue.  
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The results show that p16, CDK6 and CCND1 mRNA genes and protein are expressed in 
both normal and human skin BCC tissues. CCND1, CDK6 and p16 mRNA can be found 
to be expressed mostly in cytoplasm. The mRNA expression in BCC is higher than 
normal skin tissue. Protein expression of CCND1 and p16 in different BCC tissue are 
greater than normal skin tissue. p16 mRNA and
 
protein expression is stronger than other 
genes. RT in situ PCR and IHC analysis data showed significant expression of CCND1, 
p16
 
mRNA and protein in BCC compared to normal skin tissue (p<0.05%). 
Investigation on Iranian samples showed the protein expression of CDK6 is not 
significant (p>0.05%) but the expression of mRNA for CDK6 gene is significant 
(p<0.05%). The findings of IHC study on tissue microarray (TMA) demonstrated 
significant protein expression of p16 and CCND1 genes (p<0.05%) which support 
findings on Iranian samples. Taken together, these data provide evidence that cell cycle 
deregulation in G1-phase is a critical event during the course of carcinogenesis of BCC.  
 
In conclusion, this study showed that p16, CDK6 and CCND1 are involved in the process 
of tumorgenesis in human BCC. p16, CDK6 and CCND1 mRNA genes are expressed to 
induce cell cycle proliferation and also the protein expression of these genes can 
influence proliferation of the cell cycle. RT in situ PCR study on ten Iranian samples 
illustrated significant expression of p16
 
(p=0.026), CDK6 (p=0.015) and CCND1 
(p=0.021) mRNA genes (p<0.05%). There is a direct correlation between p16 and 
CCND1 and also between p16 and CDK6. There is no correlation between CCND1 and 
CDK6. IHC analysis on the Iranian samples demonstrated significant protein expression 
of p16 (p=0.019) and CCND1 (p=0.021) (p<0.05%) but CDK6 protein expression is not 
significant (p=0.082). Direct correlation between p16 and CCND1 was obtained. TMA 
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samples were used for the IHC study only for p16 (p=0.008) and CCND1 (p=0.024) due 
to insufficient tissue to perform complete study with IHC. Even CDK6 could not be done 
because of insufficient samples then the result
 
of TMA samples using IHC supports the 
findings on the Iranian samples about protein expression of CCND1 and p16 genes. RT 
in situ PCR is a sensitive method to study specific mRNA genes. However there are 
problems in getting good results as well as their interpretation. IHC on the other hand 
shows more reliable results. These methods may be used in the clinical setting and as it 
can be used to predict tumor behavior including cellular proliferation which can affect 
the mode of therapy. 
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Kanser sel asas (basal cell carcinoma, BCC) adalah kanser kulit yang paling biasa 
berbanding kanser-kanser kulit yang lain. Kes-kes penyakit cutaneous malignant 
melanoma (CMM) dan non-melanoma kanser kulit (MSC) di serantau dunia telah 
meningkat sebanyak 600% dari tahun 1940. Karsinogenesis adalah satu proses pelbagai 
langkah yang meliputi pelbagai perubahan kandungan genetik. Hubungan di antara 
kitaran sel dan penyakit kanser menjadi begitu rapat jika mengambil pertimbangan 
bahawa perkembangan dan pergandaan sel-sel yang tidak normal merupakan tanda yang 
mustamat bagi penyakit kanser. Penyakit kanser telah dihubungkan dengan gangguan 
dalam proses regulasi kitaran sel. Kajian yang terbaru menunjukkan bahawa gen-gen 
mRNA p16, CDK6 dan CCND1 dan pernyataan protein gen-gen tersebut terlibat dalam 
tumorigenesis penyakit kanser. Gen-gen tersebut memainkan peranan dalam 
perkembangan kitaran sel. Hasil kajian kami telah menunjukkan pernyataan cyclin, satu 
cyclin dependent kinase, dan satu cyclin kinase inhibitor yang terdapat pada basal sel 
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kulit kanser dengan mengunakan blok tisu. Transkripsi Terbalik Tindakbalas Rantaian 
Polimerase (RT in situ PCR) dan immunohistochemistri (IHC) telah kami gunakan 
untuk mengesan ekspresi gen-gen mRNA p16, CDK6 dan CCND1 serta pernyataan 
protein dalam tisu kulit kanser sel basal manusia.  
 
Hasil kajian kami juga telah menunjukkan bahawa gen-gen mRNA p16, CDK6 dan 
CCND1 serta protein di ekspres dalam kedua-dua tisu yang sihat serta tisu kanser kulit 
sel basal manusia. Keputusan kami juga menunjukkan ekspresi gen-gen mRNA CCND1, 
CDK6 dan p16 banyak didapati pada sitoplasma sel. Walau bagaimanapun, mRNA 
tersebut di ekspres secara berlebihan dengan intensi yang lebih tinggi pada tisu kanser 
berbanding dengan tisu sihat. Pengekspresan protein jenis CCND1 dan p16 dalam 
pelbagai tisu di Iran adalah lebih tinggi berbanding tisu normal kulit di mana gen p16 
mRNA dan pengekspresan protein lebih kuat berbanding gen-gen lain. Data daripada RT 
in situ PCR dan analisis IHC menunjukkan pertambahan regulasi yang jelas bagi 
CCND1 dan p16 mRNA serta protein-proteinnya pada tisu basal barah berbanding 
dengan tisu kulit yang sihat (p<0.05%). Satu kajian yang dijalankan ke atas orang Iran 
telah menunjukkan pengekspresan protein CDK6 tidak signifikan (p>0.05%) manakala 
pengekspresan mRNA adalah signifikan (p<0.05%). Tambahan pula, keputusan kajian 
yang dijalankan oleh IHC ke atas TMA (tissue microarray) menunjukkan keputusan 
yang signifikan bagi pengekspresan protein p16 dan CCND1 genes (p<0.05%). 
Keputusan ini telah membuktikan bahawa ketidakpengawalaturan kitaran sel dalam fasa 
G1 adalh kejadian yang kritikan semasa pembentukkan BCC. 
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Sebagai kesimpulan, kajian ini menjelaskan bahawa p16, CDK6 dan CCND1 telah 
terlibat dalam proses permulaan tumor dalam BCC manusia. p16, CDK6 dan gen CCND1 
mRNA diekspreskan untuk merangsangkan kitaran pembiakan sel dan ekspresan protein 
gen ini akan mempengaruhi pembiakan kitaran sel. Kajian RT in situ PCR yang 
dijalankan ke atas sepuluh orang Iran telah menunjukkan keputusan signifikan ekpresan 
p16
 
(p=0.026), CDK6 (p=0.015) dan CCND1 (p=0.021) mRNA genes (p<0.05%). 
Terdapat satu korelasi terus di antara p16 dan CCND1 dan di antara p16 dan CDK6. di 
samping itu, tiada korelasi didapati di antara CCND1 dan CDK6. Analisis IHC yang 
dijalankan ke atas sample orang Iran menunjukkan keputusan yang signifikan ke atas 
ekpresi protein p16 (p=0.019) dan CCND1 (p=0.021) (p<0.05%) tetapi tidak signifikan 
bagi ekspresi protein CDK6 (p=0.082). tambahan pula, terdapat korelasi terus antara p16 
dan CCND1. TMA hanya telah digunakan untuk menjalankan IHC bagi p16 (p=0.008) 
dan CCND1 (p=0.024). Keputusan IHC dan TMA telah menyokong menemuan terhadap 
sample orang Iran tentang ekspresi protein gen-gen tersebut. RT in situ PCR adalah 
kaedah yang sensitive untuk mengkaji gen mRNA spesifik dan IHC menunjukkan 
ekspresi protein semasa pengawalaturan kitaran sel dan peningkatan kanser. Kaedah ini 
boleh digunakan untuk mengenalpasti sel metastatic tumoral dan meramal tanda-tanda 
awal dan memilih terapi yang terbaik untuk kanser. 
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CHAPTER 1 
 
INTRODUCTION 
 
Human cytogenetics was born in 1956 with the discovery of 46 chromosomes in normal 
human cells. Three years after the structure of the DNA helix was elucidated 
cytogeneticist could do karyotype analysis since 1968. The first observation of human 
chromosomes was in the 1880s after which the full complement of the 46 human 
chromosomes were counted. However, soon after the number 46 was firmly established 
scientists readily applied the new cytogenetic technique to the investigation of 
phenotype-genotype correlations in humans and began to utilize useful information from 
naturally occurring chromosomal rearrangements (Barbara, 2002).  
 
There are over 3,000 diseases known to be caused by a single gene defect and 
chromosomal anomalies are found in over 1 in 700 live births (Nora and Fraser,1989). In 
addition, research has demonstrated that genetic viability affects many aspects of health, 
ranging from heart disease to cancer (Evans, 1988; Ashby and Richardson, 1985). It has 
long been speculated that genetically determined variation in susceptibility may 
predispose some workers to occupational disease while others in the same environment 
seem to be unaffected (Hart and Brusick,1987; Puck and Waldren, 1987; Sorsa and 
Yager, 1987). 
   
In addition, certain environmental agents are known to cause mutation in normal somatic 
cells which lead to cause diseases. Recognition of genetic factors in disease presents 
 2 
new opportunities for detection, prevention, and treatment. Because of uncertainties 
about the exact nature of the relationship between genes and environment, genetic 
monitoring and screening of otherwise healthy populations remain problematic (Schulte 
and Halperin, 1987). The relationships between genes, mutations, and disease are 
becoming clearer with the development of molecular techniques that enhance both the 
quantitative and qualitative evaluation of mutation (Honard, 1988).  
 
In many cases, mutagens are also carcinogens, so at high exposure levels, the most 
common manifestation of genetic damage is in the form of cancer (Ward, 1985). The 
damage will be resolved in one of three ways: cell death, successful DNA repair or 
viable mutation. It is difficult to establish the causal relationships between the mutation 
and cancer because of the long latency of human cancer (Nora and Fraser, 1989). The 
type of alteration produced by physical and chemical agents depends on the lesions 
induced in the DNA and, therefore, on the chemical structure of the genotoxic substance 
(Carrano and  Natarajan, 1988). 
 
Epidemiological, clinical, and biological studies have indicated that solar ultraviolet 
radiation is the major etiological agent in skin cancer development (Miller and 
Weinstock, 1994; Brash et al., 1991). The common, wavelengths in the UVB (280–320 
nm) region of the solar spectrum are absorbed by the skin, producing erythema, burns, 
and eventually skin cancer (Young, 1990; Parrish et al., 1982). Studies using laboratory 
animals have shown that UVB radiation is very efficient in inducing skin cancer (De 
Gruijl, 1995; Urbach, 1978). In fact, some early investigators began to analyze the 
process, and they defined the concepts of tumor initiation and promotion as well as co-
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carcinogenesis in operational terms (Friedelwald and Rous, 1944; BoutweHll, 1964). 
These sequential events were also found to occur in liver, urinary bladder, breast, cheek 
pouch, esophagus, colon, stomach, lung, and prostate (Walaszek et al., 2004; Slaga et 
al., 1995; Slaga, 1983). DNA damage together with the cellular response to that damage 
can establish genomic instability through multiple pathways (Limoli et al., 1997).  
 
In the present study RT in situ PCR and immunohistochemistry (IHC) was performed in 
order to determine CDK6, p16, CCND1 mRNA and protein expression in the human skin 
BCC. Positive and negative regulatory proteins control exit from or entry into the G0 
quiescent state. G1 cyclin-dependent kinases (CDKs) serve as positive regulators. D-type 
cyclin (D1, D2, D3) complex with CDK4 and CDK6 to stimulate their kinase activities, 
which in turn cause the phosphorylation and inactivation of the retinoblastoma (Rb) 
tumor suppressor protein. By binding to E2F, Rb recruits histone deacetylases to the 
promoters of E2F-responsive genes and represses their transcription (Harbour and Dean, 
2000).  
 
In this pathway p53 and pRb genes are involved in the control of G1/S phase cell cycle 
progression and proliferation. Inactivation of these tumor suppressor genes (TSG) results 
in dysfunction of proteins that normally inhibit cell cycle progression. pRb is the most 
important CDK substrate during G1 and it is frequently mutated in human cancers. 
Absence or loss of function of pRb is associated with unrestrained cell cycle progression 
(Vermeulen 2003).  
 
